Article
Effectiveness of high-dose third-generation EGFR-tyrosine kinase inhibitors in treating EGFR-mutated non-small cell lung cancer patients with leptomeningeal metastasis.
Lung cancer (Amsterdam, Netherlands) - 1 Feb 2024
Wu Haicheng, Zhang Qian, Zhai Wanchen, Chen Yunfei, Yang Yehao, Xie Mingning, Huang Zhiyu, Xu Yanjun, Li Hui, Gong Lei, Yu Sizhe, Fan Yun, Chen Kaiyan
Abstract excerpt
BACKGROUND: Leptomeningeal metastasis (LM) is associated with an extremely poor prognosis in patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). The third-generation EGFR-tyrosine kinase inhibitors (TKIs), currently the preferred drug of choice, have significantly improved treatment outcomes in these patients. However, the optimal dose of third-generation EGFR-TKIs...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.